IBM adds market value of Adidas after Trump’s quantum computing push

The US unveiled a more than $2 billion quantum-computing funding package under the CHIPS Act, including $1 billion for IBM to build a quantum chip foundry and standalone company Anderon, plus $375 million for GlobalFoundries and awards of about $100 million each to other firms. IBM said it will also invest an additional $1 billion of its own capital, while the federal government takes equity stakes in the recipient companies. IBM shares jumped more than 12%, adding over $27 billion in market value, and Rigetti, D-Wave and Infleqtion all surged more than 30% on the news.

Analysis

This is less a one-day sympathy rally than a state-backed capital-markup event for the entire quantum stack. IBM is the clearest winner because the award effectively de-risks a capex-heavy manufacturing buildout and creates a high-profile anchor customer / policy halo that should lower future cost of capital; the market is starting to value IBM not just on legacy cash flow but on a strategic industrial platform with optionality. The second-order beneficiary is GFS: if quantum wafers require adjacent advanced fabrication capability, foundry capacity, tooling, and process know-how become the bottleneck, so the order flow can spill into traditional semi supply chains even if unit economics are still immature.

The public pure-play names likely saw an overshoot in the first move. Their business models still face long commercialization runways, and government equity stakes can cut both ways: it validates the category, but it also caps the “free option” narrative by implying tighter oversight, milestone risk, and possible dilution or contractual restrictions. In other words, the news is bullish for sector survival, but not necessarily for near-term equity compounding; the market is front-running a revenue model that may remain years away.

The key catalyst path is months, not days: follow-on procurement, state-level incentives, and whether the IBM-led foundry becomes the reference architecture for additional public/private awards. The contrarian risk is that this becomes a crowded thematic trade with little fundamental throughput; if no additional contracts land in the next 1-2 quarters, the speculative names can retrace sharply while IBM likely holds a larger share of the premium because it has operating earnings to absorb disappointment. The move is probably underdone for legacy incumbents with real fabrication leverage and overdone for the smallest quantum equities that traded on scarcity rather than cash generation.

Key Decisions for Investors

• Long IBM vs short RGTIW/QBTS basket for 1-3 months: express the view that policy support accrues to the industrial incumbent more than to duration-sensitive pure plays; target a 10-15% relative outperformance if the trade cools.
• Initiate a tactical long GFS on any post-news pullback over the next 1-2 weeks: the market may be underestimating downstream foundry and process-spend spillover; use a tight stop if the stock re-rates beyond the initial policy premium.
• Sell upside calls or call spreads on QBTS into strength for the next 30-60 days: speculative momo likely dominates near term, but fundamentals remain too early-stage to justify a sustained vertical move.
• Pair trade: long IBM / short INTC as a policy-quality spread over 3-6 months: both benefit from industrial policy, but IBM has a cleaner new growth narrative and less execution drag from legacy PC/CPU cycles.
• Do not chase NVDA here: zero direct linkage in the data and the thematic bid risks creating false positive correlation; use it only as a market hedge if quantum sentiment spills into broad AI/compute beta.